PathoQuest Names Dr. Christiane Honisch to Board of Directors
PARIS, FRANCE – September 25, 2018 — PathoQuest, a genomic expert dedicated to the microbiology testing market, the leader in clinical diagnostics and biologics testing applications, today announced the appointment of Christiane Honisch, Ph.D. as an independent member of the Company’s Board of Directors.
“We are enthused to have Christiane join our Board of Directors and believe her broad experience associated with the application and commercialization of scientific innovations, transformational cutting-edge technologies, and laboratory instrumentation will bring important additional perspective to the Board,” stated Benedikt von Braunmühl, Chairman of PathoQuest’s Board of Directors. “Her tremendous insight on the microbiological application of next-generation sequencing to clinical infectious diseases is especially welcomed since this will assist us to drive our efforts with iDTECT™ Blood going forward.”
“I am very excited at the opportunity to join PathoQuest’s Board of Directors and support a fast-growing company that is leveraging its unique proprietary approach to the identification of microorganisms in a clinical setting,” said Dr. Honisch. “I look forward to sharing my experience and expertise in the field of infectious diseases and the business relationships I have built over my career working with sequencing and other technologies.”
Dr. Honisch is currently Head of Global Business Intelligence and Development at Eppendorf AG, a leading Life Science company. She has over 15 years of experience developing markers, assays, software, and cutting-edge technology for Life Science applications and infectious disease detection, monitoring, and characterization. She was formerly the Director of Microbiology Markets at Illumina, Inc. where she was responsible for the development of the company’s next-generation sequencing microbiology and virology market strategy. Prior to this, she was the Director of Infectious Disease Research at Roche Molecular Diagnostics responsible for IVD research and microbial surveillance. Her team received the Roche Innovation Award in 2014. Previously she was a key individual in developing the commercial use of nucleic acid-based mass spectrometry for DNA sequencing and microbial analysis at Sequenom, Inc. Dr. Honisch holds a diploma in chemistry and received her Ph.D. in molecular biology and microbiology from the University Carolo-Wilheimina zu Braunschweig, Germany and the German National Center for Biotechnology (GBF) in the field of the diagnosis and typing of tuberculosis.
About iDTECT™ Blood
PathoQuest has developed iDTECT Blood, the first and only clinical CE IVD metagenomic test for infectious disease diagnosis. Using a single blood sample, the test provides clinicians and microbiologists with a culture-free method for detecting more than 1,200 bacterial or viral pathogens in a turn-around time of 48 hours. The test is run in expert microbiology laboratories, accredited for the method, which allows to minimize the time between sampling and laboratory processing and to streamline the interactions and decision process between microbiologists and the treating clinical team.
PathoQuest, a spin-out of Institut Pasteur, is a life sciences company offering a game-changing metagenomics approach to improving pathogen detection in biological samples. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform and a proprietary sample preparation process which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline. The company’s solution provides microbiologists and clinicians with a comprehensive analysis covering all known clinically relevant human pathogens.
Based on the company’s technological platform, PathoQuest also offers biopharmaceutical companies a disruptive approach to secure the production of biologics like vaccines and recombinant proteins. PathoQuest’s Biological Genomic Services are currently being utilized by several major biopharma companies. A strategic partnership has been recently signed in that field with Charles River Laboratories.